BridgeBio Pharma (BBIO) AI Stock Analysis

• Market Cap: $9.56B
• Dividend Yield: N/A
• Average Volume (3M): 2.71M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.30
• Revenue Growth: 7.62%
• EPS Growth: -55.29%
• Country: US
• Employees: 725
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 191,168,500
• 10 Day Avg. Volume: 2,244,613
• 30 Day Avg. Volume: 2,714,818
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.06
• Enterprise Value/Revenue: 43.07
• Enterprise Value/Gross Profit: 44.49
• Enterprise Value/Ebitda: -15.78
• 1Y Price Target: $63.29
• Price Target Upside: 22.11% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 19

• Rating: 58 Neutral
• Price Target: $51.00 ▼(-1.60% Downside)

BridgeBio Pharma's overall stock score is driven by strong technical indicators and positive earnings call highlights, which are offset by financial instability and valuation concerns. The company's robust revenue growth and successful product launch are significant strengths, but profitability challenges and competitive pressures remain key risks.

Positive Factors

Financial Outlook

With cash on hand, growing top-line, and flattening or declining expenses, the company is well-positioned financially.

Market Performance

ATTRUBY™ (acoramidis) sales in the U.S. continue to beat expectations, showing strong market performance.

Pipeline Readouts

BridgeBio is added to the Positive Catalyst Watch List ahead of key pivotal readouts for the pipeline.

Negative Factors

Market Competition

The ATTR-CM market is large enough to support multiple modality winners, with Attruby expected to become the market share leader in the coming years.

BridgeBio Pharma Business Overview & Revenue Model

Company Description

BridgeBio Pharma (BBIO) is a biotechnology company focused on developing innovative therapeutics for genetic diseases and cancers. The company operates primarily in the pharmaceutical sector, leveraging advanced genetic insights to identify and develop targeted therapies. BridgeBio specializes in creating treatments that address the underlying genetic causes of diseases, with a robust pipeline of product candidates across various stages of clinical development.

How the Company Makes Money

BridgeBio Pharma generates revenue primarily through the development and commercialization of its therapeutic products. The company earns money through product sales once its therapies receive regulatory approval and are launched in the market. Additionally, BridgeBio may engage in partnerships and collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales. These strategic alliances can enhance revenue streams and provide necessary funding for ongoing research and development. Furthermore, BridgeBio may also receive grant funding for specific projects, contributing to its overall earnings.

BridgeBio Pharma Financial Statement Overview

Summary

BridgeBio Pharma shows strong revenue growth but faces significant profitability and financial stability challenges. The high gross profit margin indicates efficient cost management, yet operational losses persist. The balance sheet reflects financial instability with negative equity, and while cash flow generation shows improvement, it remains negative overall.

Income Statement

BridgeBio Pharma shows a strong revenue growth rate of 54.42% in the TTM, indicating a positive trajectory in sales. However, the company faces significant profitability challenges with a negative net profit margin of -5.24% and EBIT margin of -4.38%, reflecting ongoing operational losses. The gross profit margin remains high at 96.95%, suggesting efficient cost management at the gross level.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in an unusual debt-to-equity ratio of -0.006. The return on equity is positive at 49.21%, but this is due to the negative equity base rather than operational efficiency. The equity ratio is not available due to negative equity, indicating potential financial instability.

Cash Flow

The cash flow statement shows a positive free cash flow growth rate of 30.23% in the TTM, indicating improved cash generation. However, the operating cash flow to net income ratio is negative, reflecting cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is covering net losses, but overall cash flow remains negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	235.81M	221.90M	9.30M	77.65M	69.72M	8.25M
Gross Profit	228.25M	218.02M	6.86M	74.21M	66.60M	5.16M
EBITDA	-643.59M	-436.83M	-565.47M	-397.44M	-533.83M	-465.75M
Net Income	-776.41M	-535.76M	-643.20M	-481.18M	-562.54M	-448.72M
Balance Sheet
Total Assets	1.08B	919.34M	546.38M	623.04M	1.01B	703.59M
Cash, Cash Equivalents and Short-Term Investments	757.34M	681.10M	434.88M	428.27M	787.51M	607.09M
Total Debt	2.68B	1.73B	1.74B	1.72B	1.73B	495.79M
Total Liabilities	2.86B	2.38B	1.89B	1.87B	1.88B	595.70M
Stockholders Equity	-1.79B	-1.46B	-1.35B	-1.25B	-870.41M	57.91M
Cash Flow
Free Cash Flow	-665.87M	-521.66M	-529.03M	-425.81M	-546.18M	-407.23M
Operating Cash Flow	-655.81M	-520.73M	-527.72M	-419.49M	-497.93M	-399.71M
Investing Cash Flow	20.39M	60.78M	54.03M	453.15M	-200.83M	-52.99M
Financing Cash Flow	837.01M	748.46M	451.54M	-13.13M	736.45M	447.19M

BridgeBio Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 51.83
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 51.83 is above the 20-day moving average (MA) of 49.63, above the 50-day MA of 47.29, and above the 200-day MA of 36.58, indicating a bullish trend. The MACD of 1.29 indicates Negative momentum. The RSI at 59.52 is Neutral, neither overbought nor oversold. The STOCH value of 73.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.

BridgeBio Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	64 Neutral	$4.72B	84.74	26.63%	―	30.96%	-38.30%
BBIO	58 Neutral	$9.56B	―	35.68%	―	7.62%	-55.29%
RVMD	52 Neutral	$7.39B	―	-46.61%	―	-100.00%	-23.49%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
LEGN	51 Neutral	$6.32B	―	-29.70%	―	75.01%	-13.20%
BPMC	50 Neutral		―		―	99.19%	48.43%
SRPT	46 Neutral	$1.77B	19.61	-4.76%	―	64.89%	-221.56%

BridgeBio Pharma Corporate Events

BridgeBio Pharma Enters Royalty Purchase Agreement

On June 27, 2025, BridgeBio Pharma, Inc. and its subsidiary Eidos Therapeutics, Inc. entered into a Royalty Interest Purchase and Sale Agreement with Acoramidis Royalty SPV, LP and LSI Financing Fund, LP. Eidos sold certain royalty rights on net sales of products containing acoramidis in the EU to the purchasers for $300 million. This agreement provides BridgeBio with immediate capital while capping the purchasers’ royalty rights and offering security interests in specific assets, potentially impacting the company’s financial strategy and stakeholder interests.

BridgeBio Pharma Annual Meeting Approves Key Proposals

BridgeBio Pharma held its Annual Meeting on June 20, 2025, where stockholders voted on several key proposals. These included the election of five Class III directors, approval of executive compensation, ratification of Deloitte & Touche LLP as the independent accounting firm, and amendments to the company’s stock option plan and certificate of incorporation. The meeting also approved the adjournment of the meeting if necessary due to insufficient votes.